Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nab-paclitaxel | Phase 4 | Phase 4 | 281 | 146 | 111 | 748 | 0 | — | — | 2003-09 |
| Chemotherapy | Phase 4 | Phase 4 | 199 | 124 | 139 | 545 | 0 | — | — | 1992-08 |
| Sintilimab | Phase 4 | Phase 4 | 152 | 86 | 42 | 309 | 0 | — | — | Oct 19, 2016 |
| Pyrotinib | Phase 4 | Phase 4 | 49 | 26 | 15 | 96 | 0 | — | — | 2013-01 |
| Hormone Therapy | Phase 4 | Phase 4 | 39 | 17 | 23 | 66 | 0 | — | — | 1989-05 |
| Firmonertinib | Phase 4 | Phase 4 | 33 | 21 | 6 | 49 | 0 | — | — | Dec 30, 2016 |
| Nimotuzumab | Phase 4 | Phase 4 | 31 | 18 | 25 | 105 | 0 | — | — | Jan 1, 2002 |
| Aspirin | Phase 4 | Phase 4 | 29 | 8 | 37 | 119 | 0 | — | — | 1992-02 |
| Carboplatin/Paclitaxel Regimen | Phase 4 | Phase 4 | 23 | 8 | 20 | 58 | 0 | — | — | 2003-03 |
| Adjuvant Chemotherapy | Phase 4 | Phase 4 | 19 | 11 | 20 | 44 | 0 | — | — | 1999-09 |
| Immune Checkpoint Inhibitor | Phase 4 | Phase 4 | 14 | 12 | 2 | 20 | 0 | — | — | Oct 26, 2017 |
| Aromatase Inhibitor | Phase 4 | Phase 4 | 12 | 5 | 4 | 28 | 0 | — | — | Nov 7, 2008 |
| Nedaplatin | Phase 4 | Phase 4 | 8 | 4 | 7 | 28 | 0 | — | — | 2008-06 |
| Carboplatin OR Cisplatin | Phase 4 | Phase 4 | 7 | 4 | 2 | 10 | 0 | — | — | Aug 27, 2019 |
| Tunlametinib | Phase 4 | Phase 4 | 6 | 6 | 1 | 14 | 0 | — | — | Sep 1, 2017 |
| Befotertinib | Phase 4 | Phase 4 | 5 | 4 | 0 | 8 | 0 | — | — | Jan 3, 2018 |
| Icotinib | Phase 4 | Phase 4 | 4 | 2 | 12 | 64 | 0 | — | — | 2009-02 |
| Paclitaxel Liposome | Phase 4 | Phase 4 | 3 | 3 | 2 | 16 | 0 | — | — | 2000-12 |
| FOLFOX-4 Regimen | Phase 4 | Phase 4 | 2 | 2 | 3 | 13 | 0 | — | — | 2007-12 |
| Taxol | Phase 4 | Phase 4 | 1 | 1 | 5 | 22 | 0 | — | — | 1991-09 |
| R-CHOP Regimen | Phase 4 | Phase 4 | 1 | 1 | 0 | 2 | 0 | — | — | Jul 1, 2017 |
| CHOP Regimen | Phase 4 | Phase 4 | 0 | 0 | 13 | 22 | 0 | — | — | 1993-01 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.